Galera Therapeutics, Inc.
Datakwaliteit: 83%
GRTX
OTC
Manufacturing
Chemicals
€ 0,04
€ 0,00
(0,00%)
Marktkapitalisatie: 3,09 M
Prijs
€ 0,04
Marktkapitalisatie
3,09 M
Dagbereik
€ 0,04 — € 0,04
52-Weeksbereik
€ 0,02 — € 0,06
Volume
1.005
Openen € 0,04
50D / 200D Gem.
€ 0,04
15,49% above
50D / 200D Gem.
€ 0,03
57,69% above
Quick Summary
Belangrijkste Punten
Negative free cash flow of -6,05 M
P/E of 0,02 — trading at a low valuation
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROIC-50,31%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio8,20
Interest CoverageN/A
Waardering
PE (TTM)
0,02
Boven sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,0 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -53,4 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | 149,05 M |
| ROE | N/A | ROA | 2697,72% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -6,05 M |
| ROIC | -50,31% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 8,20 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 4,30 M | Tangible Book Value | -149,22 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 0,02 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -195,51% | ||
| Market Cap | 3,09 M | Enterprise Value | -1,38 M |
| Per Share | |||
| EPS (Diluted TTM) | 0,64 | Revenue / Share | N/A |
| FCF / Share | -0,08 | OCF / Share | -0,08 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | -4,06% |
| SBC-Adj. FCF | -6,92 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | 149,05 M | -18,96 M | -59,08 M | -62,22 M | -80,53 M |
| EPS (Diluted) | 0,64 | -0,34 | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -2,54 M | -20,16 M | -49,26 M | -51,23 M | -73,37 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 349.000,0 | 3,15 M | 24,12 M | 31,01 M | 52,42 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 0,0 | 20.000,0 | 259.000,0 | 114.000,0 | 778.000,0 |
| Interest Expense | 0,0 | 0,0 | 11,41 M | 11,57 M | 7,19 M |
| Income Tax | 0,0 | -203.000,0 | 0,0 | 70.000,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 7,20 M | 10,10 M | 26,14 M | 44,04 M | 83,31 M |
| Total Liabilities | 645.000,0 | 153,77 M | 157,33 M | 153,22 M | 141,32 M |
| Shareholders' Equity | 3,97 M | -148,04 M | -131,19 M | -109,18 M | -58,00 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 6,38 M | 8,29 M | 18,26 M | 4,27 M | 19,86 M |
| Current Assets | 7,10 M | 10,00 M | 21,63 M | 38,54 M | 77,39 M |
| Current Liabilities | 645.000,0 | 1,67 M | 4,96 M | 13,38 M | 12,94 M |
{"event":"ticker_viewed","properties":{"ticker":"GRTX","listing_kind":"stock","pathname":"/stocks/grtx","exchange":"OTC","country":"US"}}